The Financing round was led by growth equity firm Stripes, and marks Hello Heart’s leadership in cardiovascular digital therapeutics and proven ability to close gaps in heart health – the number one cause of death in the U.S. MENLO PARK, Calif.–(BUSINESS WIRE)–Hello Heart, the only digital therapeutic that focuses on […]
Other News
Medical Monitoring Pioneer Announces the Limited Market Release of the Masimo W1™ Watch for Consumers
On Its Anniversary, the Inventor of Measure-through Motion and Low Perfusion™ Pulse Oximetry Introduces the First Health Watch to Offer Accurate, Continuous Measurements IRVINE, Calif.–(BUSINESS WIRE)–Masimo (NASDAQ: MASI) marks its 33rd anniversary today by announcing the limited market release of the W1™ health watch for consumers. The first of its kind, the […]
Northwell cardiac surgery, cardiology programs rank among New York’s best
Five Northwell hospitals on Long Island and NYC distinguished for superior cardiac outcomes NEW HYDE PARK, NY – Two newly released New York State Department of Health (DOH) reports rank five Northwell Health hospitals as among the state’s best for cardiac surgery and percutaneous coronary interventions (PCI), a non-surgical procedure […]
Tesseract Health Appoints Dr. Michael McConnell as Head of Cardiovascular and Digital Health
Former Google Health Executive to Expand Cardiovascular Strategy for Ocular Health Technology Company GUILFORD, Conn., April 28, 2022 — Tesseract Health, a health technology company developing a portable, non-invasive platform to detect health conditions through the eyes, proudly announces the appointment of Michael McConnell, MD, MSEE, as Tesseract’s Head of […]
Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott’s Ablation Device Remain Symptom-Free for at Least 15 Months
Treatment with the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ resulted in patients with persistent atrial fibrillation experiencing an improved quality of life The catheter is part of Abbott’s suite of electrophysiology solutions designed to improve procedures to address cardiac arrythmias ABBOTT PARK, Ill., April 29, 2022 /PRNewswire/ — Abbott (NYSE: ABT) today […]
Boston Scientific Receives FDA Clearance for the EMBOLD™ Fibered Detachable Coil
MARLBOROUGH, Mass., April 28, 2022 – Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EMBOLD™ Fibered Detachable Coil, which is indicated to obstruct or reduce the rate of blood flow in the peripheral vasculature. The first procedure using the device was performed this week […]
ADONA MEDICAL, A SHIFAMED PORTFOLIO COMPANY, SECURES $37.5M IN SERIES B FINANCING
Company looks to finalize development of its advanced interventional approach for heart failure management CAMPBELL, Calif., April 29, 2022 /PRNewswire/ — Adona Medical, a Shifamed portfolio company, announced today it has secured $37.5M Series B financing, which will be used to complete product development and support further evaluation of the company’s next-generation heart failure […]
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery
MONMOUTH JUNCTION, N.J., April 29, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D) double-blind, randomized, controlled clinical trial designed to […]
Impulse Dynamics Launches Optimizer Smart Mini CCM Delivery System
Smaller, Smarter, Long-lasting Device Gives Patients a Reason To Believe There Is a Tomorrow MARLTON, N.J., April 29, 2022 (GLOBE NEWSWIRE) — Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), is proud to announce today both FDA and CE Mark […]
Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022 NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2022. Financial highlights Net cash usage […]
Recent
CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026
FDA approves Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
GE HealthCare unveils the next generation of the Vivid cardiovascular ultrasound portfolio, enabling advanced cardiac imaging across care settings
Popular
- No commented posts yet